Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575595 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT06575595 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 60 participants.
The verdict
NCT06575595, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objectives of the study are to characterize the pharmacokinetics (PK) of a single subcutaneous (SC) dose of tulisokibart (MK-7240) administered via autoinjector (AI) (Treatment A) and to characterize the PK of different concentrations of tulisokibart following SC administration of a single dose via vial/syringe (Treatments B and C). There is no formal hypothesis.
Interventions
- BIOLOGICAL Tulisokibart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575595
The ClinicalTrials.gov registry entry for NCT06575595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tulisokibart is the first listed.
NCT06575595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06575595 about?
NCT06575595 is a clinical study titled "Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)". The primary objectives of the study are to characterize the pharmacokinetics (PK) of a single subcutaneous (SC) dose of tulisokibart (MK-7240) administered via autoinjector (AI) (Treatment A) and to characterize the PK of different concentrations of tulisokibart following SC administration of a sing...
What is the current status of trial NCT06575595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-09-24. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT06575595?
The interventions under investigation include: Tulisokibart (BIOLOGICAL).
Who is sponsoring clinical trial NCT06575595?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.